JP2022521851A5 - - Google Patents

Info

Publication number
JP2022521851A5
JP2022521851A5 JP2021559062A JP2021559062A JP2022521851A5 JP 2022521851 A5 JP2022521851 A5 JP 2022521851A5 JP 2021559062 A JP2021559062 A JP 2021559062A JP 2021559062 A JP2021559062 A JP 2021559062A JP 2022521851 A5 JP2022521851 A5 JP 2022521851A5
Authority
JP
Japan
Prior art keywords
cells
use according
raav8
vector
raav8 vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/026356 external-priority patent/WO2020206098A1/en
Publication of JP2022521851A publication Critical patent/JP2022521851A/ja
Publication of JP2022521851A5 publication Critical patent/JP2022521851A5/ja
Priority to JP2025083822A priority Critical patent/JP2025131621A/ja
Pending legal-status Critical Current

Links

JP2021559062A 2019-04-03 2020-04-02 眼の病態に対する遺伝子療法 Pending JP2022521851A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025083822A JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962828949P 2019-04-03 2019-04-03
US62/828,949 2019-04-03
US201962856533P 2019-06-03 2019-06-03
US62/856,533 2019-06-03
US201962946158P 2019-12-10 2019-12-10
US62/946,158 2019-12-10
PCT/US2020/026356 WO2020206098A1 (en) 2019-04-03 2020-04-02 Gene therapy for eye pathologies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025083822A Division JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Publications (2)

Publication Number Publication Date
JP2022521851A JP2022521851A (ja) 2022-04-12
JP2022521851A5 true JP2022521851A5 (https=) 2023-04-11

Family

ID=70480820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559062A Pending JP2022521851A (ja) 2019-04-03 2020-04-02 眼の病態に対する遺伝子療法
JP2025083822A Pending JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025083822A Pending JP2025131621A (ja) 2019-04-03 2025-05-20 眼の病態に対する遺伝子療法

Country Status (13)

Country Link
US (1) US20220143221A1 (https=)
EP (2) EP4667578A3 (https=)
JP (2) JP2022521851A (https=)
KR (2) KR20220004987A (https=)
CN (2) CN113966236A (https=)
AU (1) AU2020253462A1 (https=)
BR (1) BR112021019825A2 (https=)
CA (1) CA3135843A1 (https=)
IL (1) IL286825A (https=)
MX (1) MX2021011889A (https=)
SG (1) SG11202110789VA (https=)
TW (1) TW202102679A (https=)
WO (1) WO2020206098A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CA3136119A1 (en) * 2019-04-10 2020-10-15 University Of Utah Research Foundation Htra1 modulation for treatment of amd
EP3752524A4 (en) * 2019-04-27 2021-11-24 Ocugen, Inc. ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASE
US20230277685A1 (en) * 2020-04-08 2023-09-07 President And Fellows Of Harvard College TGFß THERAPY FOR OCULAR AND NEURODEGENERATIVE DISEASES
CN111826386B (zh) * 2020-07-30 2022-02-01 西南大学 一种调控棉花纤维呈色的融合基因及其表达载体和应用
AU2021358781A1 (en) * 2020-10-07 2023-05-18 Tern Therapeutics, Llc Gene therapy for ocular manifestations of cln2 disease
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
CN116964209A (zh) * 2021-02-12 2023-10-27 格雷菲克斯公司 视网膜疾病的基因治疗
US20240316219A1 (en) * 2021-05-03 2024-09-26 North Carolina State University Compositions and methods related to the treatment of ocular diseases in equines
JP2024525183A (ja) * 2021-06-18 2024-07-10 イカロベック リミテッド 網膜障害
JP2025503637A (ja) * 2022-01-09 2025-02-04 クリヤ セラピューティクス， インコーポレイテッド 治療用抗ｉｇｆ－１ｒ抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
CN115137553A (zh) * 2022-07-11 2022-10-04 上海市同济医院 一种免造孔视网膜下液排出装置
JPWO2024048688A1 (https=) * 2022-08-31 2024-03-07
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB
CN116965768B (zh) * 2023-07-07 2024-01-19 中山大学中山眼科中心 一种自动定量分析眼内前房炎症程度的系统
WO2026011181A1 (en) * 2024-07-05 2026-01-08 Wisconsin Alumni Research Foundation Design and application of novel photoreceptor-specific promoters for retinal gene therapy applications

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US878575A (en) 1906-12-31 1908-02-11 Isaac Stevenson Ore dredging and separating apparatus.
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
AU719001B2 (en) 1994-12-29 2000-05-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
JP2003524368A (ja) 1997-08-26 2003-08-19 アリアド ジーン セラピューティクス インコーポレイテッド ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白
JP2001514007A (ja) 1997-08-27 2001-09-11 アリアド ジーン セラピューティクス インコーポレイテッド キメラ転写アクチベーター、ならびにそれに関連する組成物および使用
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
JP2002503667A (ja) 1998-02-13 2002-02-05 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 新規な二量体化剤、その製造および使用
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
US20040208847A1 (en) * 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
KR20130050939A (ko) * 2010-04-12 2013-05-16 가부시키가이샤 아루떼꾸 우에노 망막 질환의 치료 방법 및 이를 위한 안과용 조성물
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
EP2559443A1 (en) * 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
US9393370B2 (en) 2012-05-24 2016-07-19 Altaviz Llc Viscous fluid injector
CA2905952A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10064752B2 (en) * 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
CN107249522B (zh) 2014-09-19 2021-04-20 奥叙拉尔有限公司 眼科递送装置
US11071643B2 (en) 2014-11-28 2021-07-27 Visionisti Oy Ocular therapeutics tool
AU2016219789B2 (en) * 2015-02-20 2021-03-25 Fondazione Telethon Methods and compositions for treating genetic eye diseases
US11154420B2 (en) 2015-09-17 2021-10-26 Oxular Limited Ophthalmic injection device
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
USD878575S1 (en) 2015-11-24 2020-03-17 Visionisti Oy Hand operated medical instrument
CA3010862A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
WO2017158365A2 (en) 2016-03-16 2017-09-21 Oxular Limited Ophthalmic delivery device and ophthalmic active agent containing compositions
KR20240005973A (ko) 2016-04-15 2024-01-12 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
IL316926A (en) * 2017-05-11 2025-01-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinosis
EP3687464A4 (en) * 2017-09-27 2021-09-29 REGENXBIO Inc. TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB
US11071824B2 (en) 2017-11-04 2021-07-27 Altaviz, Llc Injection devices and methods for making and using them
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system
JP2022527116A (ja) * 2019-04-08 2022-05-30 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｔｐｐ１を発現するａａｖの投与による眼のリソソーム蓄積症の治療

Similar Documents

Publication Publication Date Title
JP2022521851A5 (https=)
JP2022153418A5 (https=)
JP2022545967A5 (https=)
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2024016207A5 (https=)
ES2908467T3 (es) Evasión de anticuerpos neutralizantes por un virus adenoasociado recombinante
AU2017336546A1 (en) Immunomodulatory fusion proteins
JP2015523060A5 (https=)
RU2018143411A (ru) Лечение комплемент-опосредуемых расстройств
JP2022516317A5 (https=)
JP2021500922A5 (https=)
JP2022522776A5 (https=)
JP2021533126A (ja) 臓器機能を制御するための遺伝子治療方法
JP2025501286A (ja) 修飾されたａａｖカプシドタンパク質及びその使用
WO2024002076A1 (zh) 一种治疗新生血管相关眼底疾病的aav药物
JP2022512589A5 (https=)
JP2023539368A5 (https=)
WO2022094106A1 (en) VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
US20230220420A1 (en) Gene therapy for bardet-biedl syndrome
JP2023539367A5 (https=)
JP2023526923A5 (https=)
US20240279324A1 (en) Multispecific antagonists
WO2020242220A1 (ko) 글루타치온-ｓ-전이효소 및 혈관 내피 성장인자, 혈관 내피 성장인자 수용체 또는 종양괴사인자-알파에 특이적으로 결합하는 표적 세포 또는 표적 단백질 결합능을 갖는 단백질을 포함하는 융합 단백질 및 이의 용도
CN118791624A (zh) 用于治疗视网膜神经退行性疾病的新型gpcr嵌合视蛋白
Wu et al. Half-life extension enhances drug efficacy in adeno-associated virus delivered gene therapy